CAMBRIDGE, England--(BUSINESS WIRE)--Jul 24, 2018--F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies (mAb²™), today announces that FS118 has successfully reached the first clinical milestone in its collaboration with Merck, a leading science and technology company.

FS118 is a first-in-class antagonist mAb² which simultaneously targets the LAG-3 and PD-L1 immuno-suppressive pathways and which has the potential to overcome tumour resistance and restore the natural anti-cancer immune response.

In May 2018, FS118 entered into a Phase I study in patients with advanced malignancies that have progressed on PD-1/PD-L1 therapy.

“Achieving this clinical milestone is a significant step in our alliance with Merck” said John Haurum, CEO of F-star. “FS118 is uniquely positioned as a first-in-class treatment for cancer patients. We are pleased with the progress being made and look forward to advancing our next mAb² molecules into the clinic.”

Under the collaboration, which was announced in June 2017, Merck has an exclusive option to acquire FS118 and a further four early stage immuno-oncology bispecific antibody programmes which are under discovery and development by F-star. Further payments are contingent on option exercise and achievement of clinical and commercial milestones with a potential total deal value reaching over €1B.

FS118 was generated using F-star’s proprietary Modular Antibody Technology™ by incorporating an anti-LAG-3 Fcab™ (Fc-region with antigen binding) into a PD-L1-specific antibody. Further information about the ongoing Phase I clinical trial is available on clinicaltrials.gov NCT03440437.

- ENDS -

About F-star

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology™ platform, we are building and progressing an extensive immuno-oncology pipeline of mAb²™, a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star’s technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.

Find out more at www.f-star.com. Connect with us via LinkedIn and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180724005354/en/

CONTACT: At F-star

Pierre Peotta

Communications Manager

+44 (0)1223 948 094

+44 (0)7392 080 279

pierre.peotta@f-star.com

or

For media enquiries

Instinctif Partners (UK and RoW)

Sue Charles/Ashley Tapp

+44 (0)20 7457 2020

F-star@instinctif.com

or

Lazar Partners (USA)

Glenn Silver

+1 212 867 1762

Gsilver@lazarpartners.com

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: F-star

Copyright Business Wire 2018.

PUB: 07/24/2018 05:00 AM/DISC: 07/24/2018 05:00 AM

http://www.businesswire.com/news/home/20180724005354/en